Fig. 8

Effects of NZ001 on MET and VEGFR2 and their downstream effectors in HCC cells. a Western blot demonstrated that NZ001 significantly inhibited the phosphorylation of MET and its downstream effectors including STAT3, AKT and ERK1/2 in HCC cells with MET-amplification and MET-overexpression (MHCC-97 L, MHCC-97H) in a dose-dependent manner, rather than in those without MET-amplification and MET-overexpression (Huh7, HepG2). Cells were treated with the indicated concentrations of NZ001 or 0.1% DMSO in DMEM containing 10%FBS for 5 h before protein extraction. b The effect of NZ001 on phosphorylation of MET and downstream effectors in patient-derived HCC cells(HCC949504:CN > 4, MET/P-MET IHC 3+; HCC91045436:CN < 4, MET/P-MET IHC 2+). c The effect of NZ001 on phosphorylation of VEGFR2 and MET phosphorylation and their downstream effectors in tumors from the established MHCC-97H xenografts (n = 3/group) treated daily with an oral dose of NZ001 at 30 mg/kg or vehicle for 3 days